Apotex Breaks New Ground In Canada With Biosimilar Bevacizumab

Apobiologix Unit Receives Health Canada Approval For Bambevi Rival To Avastin

Apotex has received Health Canada approval for its Bambevi bevacizumab rival to Avastin, with the firm citing the nod as a first for its Apobiologix division.

Canada Flag Vial Syringe
Apotex has received Health Canada approval for bevacizumab • Source: Alamy

Apotex has received Health Canada approval for its Bambevi (bevacizumab) biosimilar rival to Avastin, with the Canadian giant’s Apobiologix unit billing the product as “its first therapeutic treatment.”

Previously, Apobiologix has received Canadian approval for and launched Grastofil (filgrastim) in 2016 and Lapelga (pegfilgrastim) in 2019, with the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.